Pegylated Humanized Monoclonal Antibody
Pegylated Humanized Monoclonal Antibody Uses, Dosage, Side Effects, Food Interaction and all others data.
Pegylated Humanized Monoclonal Antibody is under investigation in clinical trial NCT02804763 (A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus).
| Trade Name | Pegylated Humanized Monoclonal Antibody |
| Generic | Dapirolizumab pegol |
| Dapirolizumab pegol Other Names | Dapirolizumab pegol, Immunoglobulin fab' g1-kappa pegylated, anti-(homo sapiens cd40lg (cd40 ligand, cd40l, tumor necrosis factor ligand superfamily member 5, tnfsf5, tumor necrosis factor related activation protein, trap, cd154)), pegylated humanized monoclonal antibody |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here Pegylated Humanized Monoclonal Antibody
